|
|
Volumn 293, Issue 16, 2005, Pages 1963-1964
|
|
Will lung cancer targeting hit its mark?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BCR ABL PROTEIN;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
GEFITINIB;
IMATINIB;
PLACEBO;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
PROTEIN KINASE INHIBITOR;
QUINAZOLINE DERIVATIVE;
ADVANCED CANCER;
BREAST METASTASIS;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CHROMOSOME TRANSLOCATION;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
COLORECTAL CANCER;
DIARRHEA;
DRUG EFFICACY;
DRUG INHIBITION;
DRUG TARGETING;
GENE MUTATION;
HUMAN;
LUNG CANCER;
LUNG NON SMALL CELL CANCER;
PRIORITY JOURNAL;
RASH;
SHORT SURVEY;
ARTICLE;
DRUG ANTAGONISM;
DRUG DELIVERY SYSTEM;
LUNG TUMOR;
ANTINEOPLASTIC AGENTS;
DRUG DELIVERY SYSTEMS;
HUMANS;
LUNG NEOPLASMS;
PROTEIN KINASE INHIBITORS;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 17544363958
PISSN: 00987484
EISSN: None
Source Type: Journal
DOI: 10.1001/jama.293.16.1963 Document Type: Short Survey |
|
Times cited : (1)
|
|
References (0)
|